Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STRIDE: EXPAREL in Lower Extremity Nerve Block
NCT03954639Phase 3Withdrawn
- Sponsor
- Pacira BioSciences
- Start
- Jun 2020
- Primary completion
- Sep 2020
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of liposomal bupivacaine in Persistent postsurgical pain (PPSP) (4 cohorts), sponsored by Pacira BioSciences. Primary endpoint: Magnitude of analgesic effect. Planned start Jun 2020; status: withdrawn.
02
Drugs
liposomal bupivacaine
03
Conditions
Persistent postsurgical pain (PPSP)
Beyond the preview
Go deeper on NCT03954639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03954639.